In Reply Thank you to Drs Huang and Liu for their thoughtful comments on our analysis of a randomized clinical trial evaluating the relationship between residual cancer burden (RCB) and event-free survival in the I-SPY2 trial.1 They raise the point that local therapy received may influence recurrence events, as prior reports have shown an increased risk of locoregional recurrence in patients receiving neoadjuvant chemotherapy.2 Additionally, they suggest incorporation of stromal features into prognostic tools, such as RCB.
Mukhtar R, Symmans WF, Esserman LJ. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer—Reply. JAMA Oncol. 2022;8(4):645–646. doi:10.1001/jamaoncol.2021.8000
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.